Service Pharmaceutique, Plateforme Fripharm, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d'Arsonval, F-69437 Lyon Cedex 03, France; Université de Lyon, Laboratoire de Pharmacie Galénique Industrielle, UMR-CNRS 5305, Plateforme Fripharm, ISPB-Faculté de Pharmacie, Université Claude Bernard Lyon 1, 8, Avenue Rockefeller, F-69373 Lyon Cedex 08, France.
Laboratoire Lorrain de Chimie Moléculaire, Faculté des Sciences et Techniques, Université de Lorraine, Boulevard des Aiguillettes, F-54506 Vandoeuvre les Nancy, France.
Int J Pharm. 2019 Feb 10;556:330-337. doi: 10.1016/j.ijpharm.2018.12.016. Epub 2018 Dec 12.
Poor bioavailability and low residence time limit the efficiency of conventional biguanide-based eye drops against Acanthamoeba keratitis. The aim of this work was to formulate an original anti-amoebic thermoreversible ocular gel combining biguanide and metalloproteases inhibitor - chelating agent. Chlorhexidine digluconate (CHX)-ethylenediaminetetraacetic acid disodium salt (NaEDTA) were compounded in poloxamer 407 saline solution. 0.02% CHX - 0.1% NaEDTA loaded thermosensitive ocular gel exhibited appropriate pH (5.73 ± 0.06), iso-osmolality (314 ± 5 mOsm/kg), viscosity (ranged between 15 and 25 mPa.s) and thermal gelation (26.5 °C and 33 °C) properties. Bioadhesion of gel was successfully tested onto isolated bovine eyes as well as the assessment of CHX penetration into the cornea. Intracorneal CHX concentration was found greater than trophozoite minimum amoebicidal concentration and minimal cysticidal concentration after 15-min and 2-h ocular exposure, respectively, while any CHX permeation through the cornea was detected (<51 ng/cm/h). Improvement of CHX ocular bioavailability was attributed to probable solubilization of tear film lipid layer by poloxamer. In vitro efficiency of CHX-NaEDTA ocular gel was confirmed from the drastic reduction of trophozoite and cyst survival (to 25% and 2%, respectively), confirming the potential of the multicomponent pharmaceutical material strategy for the treatment of Acanthamoeba keratitis.
传统基于双胍类的眼药水由于生物利用度差和滞留时间短,其治疗棘阿米巴角膜炎的效果有限。本研究旨在制备一种结合双胍类和金属蛋白酶抑制剂-螯合剂的新型抗阿米巴热可逆眼科凝胶。洗必泰葡萄糖酸(CHX)-乙二胺四乙酸二钠(NaEDTA)复合于泊洛沙姆 407 盐溶液中。载有 0.02%CHX-0.1%NaEDTA 的热敏感眼用凝胶具有合适的 pH 值(5.73±0.06)、等渗性(314±5mOsm/kg)、黏度(15-25mPa.s 之间)和热凝胶化(26.5°C 和 33°C)特性。成功地对离体牛眼进行了凝胶的生物黏附性测试,并评估了 CHX 穿透角膜的情况。在 15 分钟和 2 小时眼部暴露后,角膜内 CHX 浓度均高于滋养体最低杀菌浓度和最小杀囊体浓度,而通过角膜的任何 CHX 渗透均未检测到(<51ng/cm/h)。CHX 眼部生物利用度的提高归因于泊洛沙姆可能对泪膜脂质层的溶解作用。CHX-NaEDTA 眼用凝胶的体外疗效证实了滋养体和囊体存活明显减少(分别为 25%和 2%),证实了多组分药物材料策略在棘阿米巴角膜炎治疗中的潜力。